Immune Checkpoint Inhibitors in Lung Cancer

Author:

Chen Yuxiao,Jian Tingfeng,Shen Yuandong

Abstract

With the fast increase in morbidity and mortality, lung cancer has become one of the greatest threats to physical health in some countries. Immune checkpoint inhibitors (ICIs) have a significant influence on the treatment landscape of lung cancer, including non-small cell lung cancer (NSCLC). This review highlights the most important ICIs used in lung cancer at present, anti-CTLA-4 and PD-1/L1. The application status, efficacy, shortcomings and prospect of each drug, including Ipilimumab (CTLA-4), Nivolumab, Pembrolizumab, and Durvalumab (PD-1/L1), are listed to show the drug indication in the current market. By comparing different drugs, the direction of ICI drug development can be more precise, which can have an important influence on choosing drugs for lung cancer treatment.

Publisher

Darcy & Roy Press Co. Ltd.

Reference37 articles.

1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018 [J]. CA: A Cancer Journal for Clinicians, 2018, 68(1): 7-30.

2. Wood D E, Kazerooni E A, Baum S L, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology [J]. Journal of the National Comprehensive Cancer Network Jnccn, 2018, 16(4):4 12-584.

3. Freddie, Bray, Jacques, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2018,68(6): 394-424.

4. Zentaro S, Kohei F, Misato O, et al. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80years or older [J]. Cancer Reports, 2021,4(6): 1405.

5. King Kong, Yao Keying, Shenxingwei, et al. Systematic evaluation and meta-analysis of PD-1/PD-L1 immunosuppressant and docetaxel in the treatment of non-small cell lung cancer [J]. Chinese Journal of Thoracic surgery, 2021, (04): 239246.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3